Mental or Behavioral Dysfunction – Page 3

Neurocrine Biosciences Reports Positive Phase 2 Results for Osavampator in Major Depressive Disorder

4 months ago talkbio0Tagged adjunctive treatment, AMPA-PAM, Biosciences, Clinical Research, Clinical Trials, Mental Depression, Neurocrine, osavampator, safety profile, SAVITRI

Neurocrine Biosciences; osavampator; Phase 2 results; major depressive disorder; AMPA-PAM; SAVITRI study; clinical trial; adjunctive treatment; depression; safety profile

Big Pharma-Backed MapLight Plots IPO to Advance Neuro Pipeline

4 months ago talkbio0Tagged Alzheimer 's disease psychosis, Biological Factors, Clinical Trials, IPO, MapLight Therapeutics, Morgan Stanley, Muscarinic Agonists, neuro pipeline, Schizophrenia, Series D financing

MapLight Therapeutics; IPO; neuro pipeline; Alzheimer’s disease psychosis; schizophrenia; M1/M4 muscarinic agonist; Series D financing; Morgan Stanley; biopharmaceutical; clinical trials

LB Pharmaceuticals Upsizes IPO to $285M, Marks First Major Biotech Listing in Months

5 months ago talkbio0Tagged IPO, IPOs, LBRX, Nasdaq, Phase III, Pounds, public entity, Schizophrenia

LB Pharmaceuticals; IPO; biotech; $285 million; LBRX; schizophrenia; Phase III; public offering; Nasdaq; 2025 biotech IPOs

LB Pharmaceuticals Raises $285M in Upsized IPO to Fund Late-Stage Schizophrenia Drug Development

5 months ago talkbio0Tagged amisulpride, Approved, Central Nervous System Agents, Depression, Bipolar, IPO, LB-102, Pounds, Schizophrenia, United States Food and Drug Administration

LB Pharmaceuticals; IPO; schizophrenia; LB-102; amisulpride; Phase 3 clinical trial; bipolar depression; biotech fundraising; CNS drugs; FDA approval

LB Pharmaceuticals Files for $228M IPO to Fund Phase III Schizophrenia Drug

5 months ago talkbio0Tagged Alzheimer 's psychosis, amisulpride, Clinical Nurse Specialists, Depression, Bipolar, IPO, LB-102, Nasdaq, Phase 3 Clinical Trials, Pounds, Schizophrenia, United States Food and Drug Administration

LB Pharmaceuticals; IPO; Phase III trial; schizophrenia; LB-102; biotech; CNS therapeutics; bipolar depression; Alzheimer’s psychosis; amisulpride; FDA; Nasdaq

Hundreds of HHS Workers Accuse RFK Jr. of Destroying Public Health Trust After CDC Attack

5 months ago talkbio0Tagged CDC, Centers for Disease Control and Prevention (U.S.), federal workers, harassment, Health, HHS, Misinformation, Public Health Trust, RFK Jr., vaccine skepticism, Violence

RFK Jr.; Health and Human Services (HHS); CDC attack; public health trust; misinformation; vaccine skepticism; harassment; violence against federal workers

Reunion Psychedelic Therapy Advances to Pivotal Trials after Postpartum Depression Success

5 months ago talkbio0Tagged Clinical Trials, Depression, Postpartum, Montgomery-Åsberg Depression Rating Scale, Montgomery-Asberg Depression Rating Scale Questionnaire, Neuroscience discipline, Phase 2 Clinical Trials, Phase 3 Clinical Trials, psychedelic therapy, RE104, RECONNECT, remission rates, Reunion

Reunion Neuroscience; RE104; psychedelic therapy; postpartum depression (PPD); Phase II trial; Phase III trial; RECONNECT trial; clinical trial results; Montgomery-Åsberg Depression Rating Scale (MADRS); remission rates

CDC Launches ‘Free Mind’ Campaign Targeting Teen Substance Use and Mental Health

6 months ago talkbio0Tagged Adolescence, Alcohol or Other Drugs use, Centers for Disease Control and Prevention (U.S.), Drug Overdose, fentanyl, Free Mind ' Campaign, mental health, Strategy, teen suicide

CDC; Free Mind campaign; youth mental health; substance use; drug overdose; fentanyl; teen suicide; coping strategies

Atai’s Schizophrenia Drug Fails to Improve Cognition in Phase 2 Study

6 months ago talkbio0Tagged Atai Life Sciences, CIAS, clinical endpoints, Clinical trial failure, Cognition, Impaired cognition, inidascamine, Recognify Life Sciences, Schizophrenia

Atai Life Sciences; Recognify Life Sciences; inidascamine; schizophrenia; cognitive impairment; Phase 2b trial; clinical trial failure; cognition; CIAS; clinical endpoints

FDA Advisory Committee Rejects Lundbeck and Otsuka’s PTSD Bid for Rexulti

6 months ago talkbio0Tagged Advisory Committees, brexpiprazole, Clinical Trials, drug efficacy, Lundbeck, Otsuka, Post-Traumatic Stress Disorder, Rexulti, sertraline, United States Food and Drug Administration

Lundbeck; Otsuka; Rexulti; FDA advisory committee; PTSD; brexpiprazole; sertraline; clinical trials; drug efficacy; setback